Progyny (NASDAQ:PGNY) COO Sells 1,879 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) COO Melissa Cummings sold 1,879 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the transaction, the chief operating officer owned 66,496 shares in the company, valued at approximately $1,861,888. This trade represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Down 2.1%

Shares of NASDAQ PGNY traded down $0.59 during midday trading on Friday, hitting $26.86. The stock had a trading volume of 919,547 shares, compared to its average volume of 1,391,005. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of 29.20, a PEG ratio of 1.92 and a beta of 1.02. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $33.06. The company has a fifty day moving average price of $26.43 and a 200 day moving average price of $25.45.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. During the same quarter in the prior year, the company earned $0.19 EPS. The company’s revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, research analysts forecast that Progyny, Inc. will post 1.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on PGNY. Truist Financial boosted their price objective on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Weiss Ratings upgraded Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Wall Street Zen upgraded Progyny from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 19th. Barclays dropped their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 12th. Finally, Citizens Jmp boosted their price target on Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.36.

Institutional Investors Weigh In On Progyny

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Progyny during the 2nd quarter worth $334,426,000. Fort Washington Investment Advisors Inc. OH lifted its holdings in Progyny by 46.9% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after buying an additional 859,289 shares in the last quarter. Bank of America Corp DE boosted its position in Progyny by 75.3% in the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock valued at $20,223,000 after buying an additional 511,609 shares during the last quarter. River Road Asset Management LLC boosted its position in Progyny by 13.9% in the 4th quarter. River Road Asset Management LLC now owns 687,824 shares of the company’s stock valued at $17,663,000 after buying an additional 83,912 shares during the last quarter. Finally, William Blair Investment Management LLC acquired a new stake in shares of Progyny during the second quarter valued at about $16,807,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.